Premium
Elucidating the molecular basis of MSH2‐deficient tumors by combined germline and somatic analysis
Author(s) -
VargasParra Gardenia M.,
GonzálezAcosta Maribel,
Thompson Bryony A.,
Gómez Carolina,
Fernández Anna,
Dámaso Estela,
Pons Tirso,
Morak Monika,
del Valle Jesús,
Iglesias Silvia,
Velasco Àngela,
Solanes Ares,
Sanjuan Xavier,
Padilla Natàlia,
de la Cruz Xavier,
Valencia Alfonso,
HolinskiFeder Elke,
Brunet Joan,
Feliubadaló Lídia,
Lázaro Conxi,
Navarro Matilde,
Pineda Marta,
Capellá Gabriel
Publication year - 2017
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.30820
Subject(s) - msh2 , germline mutation , msh6 , lynch syndrome , germline , mutyh , biology , genetics , dna mismatch repair , mlh1 , cancer research , mutation , colorectal cancer , cancer , gene
In a proportion of patients presenting mismatch repair (MMR)‐deficient tumors, no germline MMR mutations are identified, the so‐called Lynch‐like syndrome (LLS). Recently, MMR‐deficient tumors have been associated with germline mutations in POLE and MUTYH or double somatic MMR events. Our aim was to elucidate the molecular basis of MSH2‐deficient LS‐suspected cases using a comprehensive analysis of colorectal cancer (CRC)‐associated genes at germline and somatic level. Fifty‐eight probands harboring MSH2‐deficient tumors were included. Germline mutational analysis of MSH2 (including EPCAM deletions) and MSH6 was performed. Pathogenicity of MSH2 variants was assessed by RNA analysis and multifactorial likelihood calculations. MSH2 cDNA and methylation of MSH2 and MSH6 promoters were studied. Matched blood and tumor DNA were analyzed using a customized next generation sequencing panel. Thirty‐five individuals were carriers of pathogenic or probably pathogenic variants in MSH2 and EPCAM . Five patients harbored 4 different MSH2 variants of unknown significance (VUS) and one had 2 novel MSH6 promoter VUS. Pathogenicity assessment allowed the reclassification of the 4 MSH2 VUS and 6 probably pathogenic variants as pathogenic mutations, enabling a total of 40 LS diagnostics. Predicted pathogenic germline variants in BUB1 , SETD2 , FAN1 and MUTYH were identified in 5 cases. Three patients had double somatic hits in MSH2 or MSH6 , and another 2 had somatic alterations in other MMR genes and/or proofreading polymerases. In conclusion, our comprehensive strategy combining germline and somatic mutational status of CRC‐associated genes by means of a subexome panel allows the elucidation of up to 86% of MSH2‐deficient suspected LS tumors.